During March 2025 the Dolutegravir market in India saw price reduction as supply exceeded demand due to plummeting interest from pharmaceutical sectors. The domestically produced materials, maintained reliability in the supply chain which supported both national markets and international export demand for Dolutegravir. The well-managed supply conditions received greater stability through encouraging macroeconomic aspects along with improved delivery systems throughout India.

• Dolutegravir prices declined in March 2025 due to ample domestic supply and reduced demand from downstream sectors.
• Government's PLI scheme boosted local production, enhancing self-reliance and contributing to market oversupply for Dolutegravir.
• Indian suppliers offered discounts to stay competitive against Chinese manufacturers, intensifying price pressure for Dolutegravir.
• Improved logistics and lower freight rates supported cost efficiencies across the supply chain.
• Experts predict short term price softness for Dolutegravir, with long term trends dependent on global economic and trade factors.

Experts from the industry stated that the Production Linked Incentive (PLI) scheme by the Indian government significantly boosted domestic pharmaceutical manufacturing and contributed to Dolutegravir production. A total financial investment of Rs 6,940 crore enabled the scheme to play an essential role in increasing local production capabilities. The initiative both promoted local independence as well as decreased import requirements for Dolutegravir supply. Indian manufacturers kept pace with Chinese suppliers through aggressive pricing plans by lowering their product prices thus accelerating the ongoing reduction in prices.

The Manufacturing Purchasing Managers' Index in India displayed a positive increase between March and February demonstrating continuous manufacturing sector growth which supported pharmaceutical production. Enhancements in rail infrastructure combined with better container handling at major ports enabled smoother material flow and reduced raw material import costs through decreasing trade route freight rates along major Asian shipping routes. In March, the increasing value of India's Rupee versus the US Dollar decreased the financial pressure of using dollar-denominated inputs which reinforced supply side cost effectiveness.

The market faced noticeable weakness in demand patterns for Dolutegravir. The market experienced procurement slowdown by pharmaceutical downstream companies because of their cautious inventory approaches and reduced product consumption. Market share retention in a competitive environment triggered domestic manufacturers to implement price reductions following their inventory growth.

Experts forecast Dolutegravir prices will undergo a short-term decrease in future months. The establishment of a short-term stability appears possible thanks to market adjustments yet substantial pricing changes will stem from global economic factors alongside currency fluctuations and political trade shifts and market consumer distribution patterns. Industry stakeholders should track regulatory shifts along with currency exchange dynamics and consumer trends since these factors will help them handle potential price disturbances for Dolutegravir.